Trial Profile

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Deucravacitinib (BMS-986165) Administered as Various Solid Oral Gastro-retentive Tablet Formulation Prototypes in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucravacitinib (Primary)
Indications Alopecia areata; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Erythrodermic psoriasis; Hidradenitis suppurativa; Lupus nephritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Sjogren's syndrome; Systemic lupus erythematosus; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

02 Jul 2025 Status changed from recruiting to completed.
20 Apr 2025 Planned End Date changed from 6 Jun 2025 to 12 Jun 2025.
20 Apr 2025 Planned primary completion date changed from 6 Jun 2025 to 12 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com